Illumina, Inc. (NASDAQ:ILMN) – Investment analysts at William Blair reduced their Q3 2018 EPS estimates for Illumina in a research report issued to clients and investors on Monday. William Blair analyst A. Murphy now forecasts that the life sciences company will earn $1.20 per share for the quarter, down from their previous forecast of $1.22. William Blair currently has a “Market Perform” rating on the stock. William Blair also issued estimates for Illumina’s Q4 2018 earnings at $1.25 EPS, FY2018 earnings at $4.55 EPS, FY2019 earnings at $5.14 EPS and FY2020 earnings at $5.87 EPS.
Several other brokerages have also recently commented on ILMN. Citigroup raised their target price on shares of Illumina from $180.00 to $220.00 and gave the stock a “neutral” rating in a report on Wednesday, October 25th. Robert W. Baird upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $184.00 to $228.00 in a report on Wednesday, October 25th. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. Barclays raised their target price on shares of Illumina from $200.00 to $215.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 31st. Finally, Cowen raised their target price on shares of Illumina from $250.00 to $275.00 and gave the stock an “outperform” rating in a report on Monday, January 22nd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the company. Illumina currently has an average rating of “Buy” and a consensus target price of $241.39.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.22. The company had revenue of $778.00 million for the quarter, compared to analysts’ expectations of $752.04 million. Illumina had a net margin of 26.56% and a return on equity of 21.52%. The business’s revenue was up 25.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.85 EPS.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $211.35, for a total value of $4,227,000.00. Following the completion of the sale, the director now directly owns 531,717 shares in the company, valued at $112,378,387.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert S. Epstein sold 1,250 shares of Illumina stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $226.55, for a total transaction of $283,187.50. Following the completion of the sale, the director now owns 9,088 shares of the company’s stock, valued at $2,058,886.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 114,440 shares of company stock valued at $25,318,904. 0.89% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ILMN. Axiom International Investors LLC DE raised its position in shares of Illumina by 60.9% in the third quarter. Axiom International Investors LLC DE now owns 186,457 shares of the life sciences company’s stock valued at $37,142,000 after purchasing an additional 70,572 shares during the period. Virtu Financial LLC bought a new position in shares of Illumina in the third quarter valued at approximately $577,000. Creative Planning raised its position in shares of Illumina by 9.8% in the fourth quarter. Creative Planning now owns 12,384 shares of the life sciences company’s stock valued at $2,706,000 after purchasing an additional 1,107 shares during the period. Gateway Investment Advisers LLC raised its position in shares of Illumina by 3.5% in the fourth quarter. Gateway Investment Advisers LLC now owns 95,711 shares of the life sciences company’s stock valued at $20,912,000 after purchasing an additional 3,202 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its position in shares of Illumina by 4.9% in the third quarter. Schwab Charles Investment Management Inc. now owns 508,368 shares of the life sciences company’s stock valued at $101,267,000 after purchasing an additional 23,647 shares during the period. Hedge funds and other institutional investors own 92.04% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.